JP2013505270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505270A5 JP2013505270A5 JP2012529982A JP2012529982A JP2013505270A5 JP 2013505270 A5 JP2013505270 A5 JP 2013505270A5 JP 2012529982 A JP2012529982 A JP 2012529982A JP 2012529982 A JP2012529982 A JP 2012529982A JP 2013505270 A5 JP2013505270 A5 JP 2013505270A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- adamts13
- months
- item
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims description 88
- 239000000203 mixture Substances 0.000 claims description 88
- 102000043853 ADAMTS13 Human genes 0.000 claims description 86
- 108091005670 ADAMTS13 Proteins 0.000 claims description 86
- 230000000694 effects Effects 0.000 claims description 34
- 238000002360 preparation method Methods 0.000 claims description 26
- 238000003860 storage Methods 0.000 claims description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 13
- 239000011575 calcium Substances 0.000 claims description 13
- 229910052791 calcium Inorganic materials 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 150000005846 sugar alcohols Chemical class 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 229940068968 polysorbate 80 Drugs 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 101000798281 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 13 Proteins 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000057210 human ADAMTS13 Human genes 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 229930003537 Vitamin B3 Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000011708 vitamin B3 Substances 0.000 claims description 2
- 235000019160 vitamin B3 Nutrition 0.000 claims description 2
- 102000051388 ADAMTS1 Human genes 0.000 claims 6
- 108091005660 ADAMTS1 Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 3
- IHBCFWWEZXPPLG-UHFFFAOYSA-N [Ca].[Zn] Chemical compound [Ca].[Zn] IHBCFWWEZXPPLG-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24435309P | 2009-09-21 | 2009-09-21 | |
| US61/244,353 | 2009-09-21 | ||
| PCT/US2010/049723 WO2011035335A2 (en) | 2009-09-21 | 2010-09-21 | Stabilized liquid and lyophilized adamts13 formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014259954A Division JP2015063556A (ja) | 2009-09-21 | 2014-12-24 | 安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013505270A JP2013505270A (ja) | 2013-02-14 |
| JP2013505270A5 true JP2013505270A5 (enExample) | 2013-11-07 |
| JP5819303B2 JP5819303B2 (ja) | 2015-11-24 |
Family
ID=43598388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529982A Active JP5819303B2 (ja) | 2009-09-21 | 2010-09-21 | 安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤 |
| JP2014259954A Pending JP2015063556A (ja) | 2009-09-21 | 2014-12-24 | 安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014259954A Pending JP2015063556A (ja) | 2009-09-21 | 2014-12-24 | 安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (9) | US8623352B2 (enExample) |
| EP (5) | EP4218797B9 (enExample) |
| JP (2) | JP5819303B2 (enExample) |
| KR (6) | KR20250008986A (enExample) |
| CN (2) | CN104224705B (enExample) |
| AU (1) | AU2010295299B2 (enExample) |
| BR (1) | BR112012006283B1 (enExample) |
| CA (1) | CA2774556A1 (enExample) |
| DK (4) | DK2480198T3 (enExample) |
| EA (1) | EA024267B1 (enExample) |
| ES (4) | ES3001509T3 (enExample) |
| FI (2) | FI3834841T3 (enExample) |
| FR (1) | FR24C1049I2 (enExample) |
| HR (1) | HRP20160295T1 (enExample) |
| HU (1) | HUE028688T2 (enExample) |
| IN (1) | IN2012DN02645A (enExample) |
| MX (3) | MX362382B (enExample) |
| NZ (1) | NZ598839A (enExample) |
| PL (4) | PL2480198T3 (enExample) |
| PT (2) | PT4218797T (enExample) |
| WO (1) | WO2011035335A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3388529A1 (en) | 2008-12-05 | 2018-10-17 | Baxalta GmbH | Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof |
| AU2010295299B2 (en) | 2009-09-21 | 2015-12-24 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized ADAMTS13 formulations |
| DK2814514T3 (en) * | 2012-02-16 | 2017-12-18 | Atyr Pharma Inc | Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases |
| CN103566362B (zh) * | 2012-07-21 | 2015-07-29 | 复旦大学 | 重组adamts13在制备脑出血药物中的用途 |
| WO2014075033A2 (en) | 2012-11-09 | 2014-05-15 | Puget Sound Blood Center | Protein stabilizing factors |
| AU2013203062C1 (en) * | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
| ES2847383T3 (es) | 2013-03-15 | 2021-08-03 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| AU2015280480A1 (en) * | 2014-06-26 | 2017-01-05 | Amgen Inc. | Protein formulations |
| GB201510870D0 (en) * | 2015-05-26 | 2015-08-05 | Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh | Treatment of infarction |
| ES2983978T3 (es) | 2016-01-08 | 2024-10-28 | Univ Kyoto | Medicina que comprende ADAMTS13 como ingrediente principal |
| KR20230079461A (ko) | 2016-08-04 | 2023-06-07 | 다케다 파머수티컬 컴패니 리미티드 | 급성 폐 손상 및/또는 급성 호흡 곤란 증후군에서 혈관폐색 위기의 치료, 개선 및/또는 예방을 위한 adamts13의 용도 |
| ES2981519T3 (es) | 2016-11-04 | 2024-10-09 | Takeda Pharmaceuticals Co | Formulaciones de virus adeno-asociados |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| UA125971C2 (uk) * | 2017-07-25 | 2022-07-20 | Джянгсу Хенгруй Медісін Ко., Лтд. | Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування |
| MX2020013953A (es) * | 2018-07-11 | 2021-03-09 | Takeda Pharmaceuticals Co | Composiciones de virus adenoasociado (aav). |
| EP4037704B1 (en) | 2019-10-04 | 2025-12-03 | The Children's Medical Center Corporation | Adamts13 treatment to enhance graft survival |
| WO2021198781A2 (en) | 2020-04-02 | 2021-10-07 | Takeda Pharmaceutical Company Limited | Adamts13 variant, compositions, and uses thereof |
| JP2023526546A (ja) | 2020-05-22 | 2023-06-21 | 武田薬品工業株式会社 | コロナウイルス疾患の合併症の治療及び診断のための、ａｄａｍｔｓ１３組成物及び方法 |
| US20230295597A1 (en) * | 2020-08-13 | 2023-09-21 | Hadasit Medical Research Services & Development Limited | A disintegrin and metalloproteinase with a thrombospondin type i motif, member 13 (adamts-13) mutants, compositions and therapeutic methods thereof |
| CA3244889A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM |
| KR20240112755A (ko) * | 2023-01-11 | 2024-07-19 | 주식회사 녹십자 | 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| AT407255B (de) | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DK1820516T3 (da) | 1999-02-22 | 2013-10-28 | Univ Connecticut | Nye albuminfrie faktor VIII-præparater |
| JP2001227510A (ja) | 2000-02-15 | 2001-08-24 | Tomoe Tech Res Co | 複作動型の空気式アクチュエータ |
| JP3783507B2 (ja) | 2000-02-16 | 2006-06-07 | 日本精工株式会社 | トロイダル型無段変速機用ディスクの加工方法 |
| US6926894B2 (en) | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| JP2003284570A (ja) | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子（ｖＷＦ）切断酵素 |
| US7037658B2 (en) * | 2001-08-16 | 2006-05-02 | Regents Of University Of Michigan | Methods and compositions for detecting variant ADAMTS13 genes |
| ITPR20010055A1 (it) | 2001-08-31 | 2003-03-03 | Vetroarredo Spa | Procedimento e impianto per la realizzazione di mattoni in vetro. |
| KR100472006B1 (ko) | 2002-10-09 | 2005-03-10 | 동부아남반도체 주식회사 | 모스 트랜지스터 제조 방법 |
| JP5112692B2 (ja) * | 2003-07-07 | 2013-01-09 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | フォンビルブランド因子（ｖｗｆ）マルチマーを検出する方法およびシステム |
| GB0404693D0 (en) * | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| PL1902141T3 (pl) | 2005-06-17 | 2012-12-31 | Baxalta Inc | Kompozycje o działaniu trombolitycznym zawierające ADAMTS13 |
| JP4880997B2 (ja) * | 2005-12-28 | 2012-02-22 | アルフレッサファーマ株式会社 | Ａｄａｍｔｓ１３の安定化方法 |
| PL3121266T3 (pl) | 2006-01-04 | 2020-07-13 | Baxalta Incorporated | Wolne od oligopeptydów pożywki do hodowli komórkowej |
| AU2010295299B2 (en) * | 2009-09-21 | 2015-12-24 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized ADAMTS13 formulations |
| US8823352B2 (en) | 2011-07-11 | 2014-09-02 | Linear Technology Corporation | Switching power supply having separate AC and DC current sensing paths |
-
2010
- 2010-09-21 AU AU2010295299A patent/AU2010295299B2/en active Active
- 2010-09-21 MX MX2016005314A patent/MX362382B/es unknown
- 2010-09-21 HU HUE10759786A patent/HUE028688T2/en unknown
- 2010-09-21 EP EP23172759.5A patent/EP4218797B9/en active Active
- 2010-09-21 PL PL10759786.6T patent/PL2480198T3/pl unknown
- 2010-09-21 PL PL20211228.0T patent/PL3834841T3/pl unknown
- 2010-09-21 FI FIEP20211228.0T patent/FI3834841T3/fi active
- 2010-09-21 NZ NZ598839A patent/NZ598839A/en unknown
- 2010-09-21 WO PCT/US2010/049723 patent/WO2011035335A2/en not_active Ceased
- 2010-09-21 DK DK10759786.6T patent/DK2480198T3/en active
- 2010-09-21 ES ES23172759T patent/ES3001509T3/es active Active
- 2010-09-21 KR KR1020247043292A patent/KR20250008986A/ko active Pending
- 2010-09-21 EA EA201200519A patent/EA024267B1/ru not_active IP Right Cessation
- 2010-09-21 KR KR1020217013486A patent/KR20210054598A/ko not_active Ceased
- 2010-09-21 BR BR112012006283-2A patent/BR112012006283B1/pt active IP Right Grant
- 2010-09-21 IN IN2645DEN2012 patent/IN2012DN02645A/en unknown
- 2010-09-21 US US12/887,424 patent/US8623352B2/en active Active
- 2010-09-21 DK DK15203085.4T patent/DK3167897T3/da active
- 2010-09-21 EP EP24192531.2A patent/EP4467160A3/en active Pending
- 2010-09-21 EP EP15203085.4A patent/EP3167897B1/en active Active
- 2010-09-21 MX MX2012003414A patent/MX339205B/es active IP Right Grant
- 2010-09-21 KR KR1020227034508A patent/KR20220139456A/ko not_active Ceased
- 2010-09-21 FI FIEP23172759.5T patent/FI4218797T3/fi active
- 2010-09-21 CN CN201410452647.8A patent/CN104224705B/zh active Active
- 2010-09-21 PT PT231727595T patent/PT4218797T/pt unknown
- 2010-09-21 ES ES15203085T patent/ES2865250T3/es active Active
- 2010-09-21 EP EP10759786.6A patent/EP2480198B9/en active Active
- 2010-09-21 ES ES10759786.6T patent/ES2579906T3/es active Active
- 2010-09-21 KR KR1020197035791A patent/KR20190137954A/ko not_active Ceased
- 2010-09-21 CA CA2774556A patent/CA2774556A1/en not_active Abandoned
- 2010-09-21 HR HRP20160295TT patent/HRP20160295T1/hr unknown
- 2010-09-21 PL PL23172759.5T patent/PL4218797T3/pl unknown
- 2010-09-21 DK DK23172759.5T patent/DK4218797T5/da active
- 2010-09-21 KR KR1020187023806A patent/KR20180095738A/ko not_active Ceased
- 2010-09-21 ES ES20211228T patent/ES2948612T3/es active Active
- 2010-09-21 KR KR1020127009803A patent/KR101891646B1/ko active Active
- 2010-09-21 PT PT202112280T patent/PT3834841T/pt unknown
- 2010-09-21 PL PL15203085T patent/PL3167897T3/pl unknown
- 2010-09-21 EP EP20211228.0A patent/EP3834841B1/en active Active
- 2010-09-21 CN CN201080046707.6A patent/CN102573792B/zh active Active
- 2010-09-21 DK DK20211228.0T patent/DK3834841T3/da active
- 2010-09-21 JP JP2012529982A patent/JP5819303B2/ja active Active
-
2012
- 2012-03-21 MX MX2019000547A patent/MX2019000547A/es unknown
-
2013
- 2013-11-22 US US14/088,169 patent/US9351935B2/en active Active
-
2014
- 2014-12-24 JP JP2014259954A patent/JP2015063556A/ja active Pending
-
2016
- 2016-05-03 US US15/145,755 patent/US9572778B2/en active Active
-
2017
- 2017-01-06 US US15/400,526 patent/US9937244B2/en active Active
-
2018
- 2018-02-28 US US15/908,213 patent/US10238720B2/en active Active
-
2019
- 2019-02-14 US US16/275,690 patent/US10758599B2/en active Active
-
2020
- 2020-07-21 US US16/934,100 patent/US11564979B2/en active Active
-
2022
- 2022-12-23 US US18/146,212 patent/US12178861B2/en active Active
-
2024
- 2024-11-19 US US18/952,409 patent/US20250099559A1/en active Pending
- 2024-12-10 FR FR24C1049C patent/FR24C1049I2/fr active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505270A5 (enExample) | ||
| JP7479068B2 (ja) | ニューレグリン調合剤の処方 | |
| US11020459B2 (en) | Factor VIII formulations | |
| KR101643277B1 (ko) | 재조합 ｖｗｆ 제제 | |
| CN102573792B (zh) | 稳定化的液体和冻干的adamts13制剂 | |
| ES2213744T3 (es) | Composiciones farmaceuticas a base de inhibidores de la interleucina-1. | |
| IL259921A (en) | A new stabilizing factor for pharmaceutical proteins | |
| JP5649451B2 (ja) | トレハロースを含む安定化第ｉｘ因子製剤 | |
| US9326944B2 (en) | Freeze-dried formulations of FGF-18 | |
| JP6895892B2 (ja) | ポンペ病のｍＲＮＡ治療 | |
| JP2024156754A5 (enExample) | ||
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| JPH04502017A (ja) | 小ペプチド類の安定化水系調剤 | |
| WO2012096411A1 (ja) | 難治性炎症性腸疾患の予防又は治療方法 | |
| AU2012268987A1 (en) | Freeze-dried formulations of FGF-18 | |
| JP2016034958A (ja) | 安定ｍｉａ／ｃｄ−ｒａｐ製剤 | |
| EP1502589B1 (en) | Veterinary aqueous injectable suspensions containing florfenicol | |
| TW202203936A (zh) | 啟動內源性抗菌藥物治療ｓａｒｓ－ｃｏｖ－２感染 | |
| Ubhe | IL-1 receptor antagonist: etiological and drug delivery systems overview | |
| KR20170072355A (ko) | C형 간염에 대한 장기 작용 약학적 조성물 | |
| JP4461727B2 (ja) | 外用剤組成物 | |
| Siegel et al. | Progress towards a prodrug/enzyme intranasal delivery for rapid prevention/reversal of seizure emergency | |
| Pasin et al. | Interventions Increasing Mortality | |
| JP2004238374A (ja) | 抗クラミジア用剤 | |
| KR20060108040A (ko) | 인 과립구 콜로니 자극인자 용액 제형 |